Schellenberg Wittmer has advised the Swedish medtech company AddLife on the acquisition of Vision Ophthalmology Group GmbH, a leading provider of ophthalmic products and services from Stirling Square Capital Partners. The initial purchase price, which can still increase by up to EUR 18 million, is EUR 165 million, of which 50 percent is being paid in cash and 50 percent via listed AddLife shares.
AddLife, listed at the Nasdaq Stockholm, owns and acquires market-leading companies in niche segments with offerings aimed primarily at the healthcare sector, from research to medical care. AddLife currently has a presence in over 25 countries, mainly in the Nordic region and the rest of Europe and has over 1,100 employees. In 2020, the group’s net sales reached over SEK 5 billion.
Vision Ophthalmology Group GmbH is a leading European provider of high-quality ophthalmic products and services. It has operations in Switzerland, Germany, the UK and Poland with Switzerland being its largest market. The group has approx. 190 employees and achieved approx. EUR 70 million sales in 2020.
With the acquisition of the Vision Ophthalmology Group, AddLife is expanding its product portfolio to include a new, strategically important therapeutic area in the growth market of ophthalmology.
The Schellenberg Wittmer team advising AddLife consisted of Dr. Lorenzo Olgiati, Christian Bonhôte, Céline Schmid, Daniele Simoniello, Elias Ritzi and Jessica Obrist (all Corporate/M&A), Dr. Lorenza Ferrari Hofer and Sarah Leins (both Life Sciences and IP), Dr. Samuel Klaus (ICT) and David Mamane (Competition).
Schellenberg Wittmer acted as Swiss legal counsel together with Swedish law firm Delphi, lead counsel for AddLife in this multi-jurisdictional transaction.
Copy linkLink copied
+41 44 215 5268